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Abstract 
 
Dyggve-Melchior-Clausen dysplasia (DMC) is a rare inherited dwarfism with severe mental 
retardation due to mutations in the DYM gene which encodes Dymeclin, a 669-aminoacid 
protein of yet unknown function. Despite a high conservation across species and several 
predicted transmembrane domains, Dymeclin could not be ascribed to any family of proteins. 
Here we show, using in situ hybridization, that DYM is widely expressed in human embryos, 
especially in the cortex, the hippocampus and the cerebellum. Both the endogenous and the 
recombinant protein fused to GFP co-localized with Golgi apparatus markers. Electron 
microscopy revealed that Dymeclin associates with the Golgi apparatus and with transitional 
vesicles of the reticulum-Golgi interface. Moreover, permeabilization assays revealed that 
Dymeclin is not a transmembrane but a peripheral protein of the Golgi apparatus as it can be 
completely released from the Golgi after permeabilization of the plasma membrane. Time 
lapse confocal microscopy experiments on living cells further showed that the protein shuttles 
between the cytosol and the Golgi apparatus in a highly dynamic manner and recognizes 
specifically a subset of mature Golgi membranes. Finally, we found that DYM mutations 
associated with DMC result in mis-localization and subsequent degradation of Dymeclin. 
These data indicate that DMC results from a loss-of-function of Dymeclin, a novel peripheral 
membrane protein which shuttles rapidly between the cytosol and mature Golgi membranes 
and point out a role of Dymeclin in cellular trafficking. 
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Introduction 
Dymeclin is a protein recently identified as the translation product of the 
FLJ20071/FLJ90130/Dym gene (DYM) which mutations are responsible for a severe 
autosomal-recessive skeletal dysplasia associated with mental delay, Dyggve-Melchior-
Clausen syndrome (DMC, MIM#223800) and a clinical variant without mental impairment, 
Smith-McCort syndrome (SMC, MIM#607326), (1 , 2). DMC/SMC skeletal features consist 
of a short trunk dwarfism with particular radiological features, severe proximal limb 
shortening and microcephaly associated with a peculiar facial dysmorphism (3). Mental 
retardation is consistently observed in DMC with an average IQ between 25 and 65. Children 
are often hyperactive, display autistic features and do not speak. Both skeletal and mental 
features are progressive in DMC, and the phenotype often leads to severe orthopedic 
complications (3).  
Dymeclin is a 669-aminoacid protein which does not belong to any identified protein family. 
Except for five or six putative transmembrane domains and a N-terminal myristoylation site, 
search for predictive structural and/or functional motives failed to provide any clue as to the 
function of Dymeclin (1 , 2). Most of the mutations identified in DYM predict the generation 
of a truncating product; however, a few frameshift mutations in the last exon predicting an 
elongated protein, two complex genomic duplications resulting in exon repetition, and two 
missense mutations have also been reported (1 , 2, 4). At the ultrastructural level, DMC cells 
disclose enlarged endoplasmic reticulum (ER) network and accretion of intracytosolic 
membranous vesicles (2 , 3, 5 , 6 ). It has therefore been proposed that Dymeclin may be an 
integral membrane protein of the ER possibly involved in the transport of intracellular 
compounds (7). Because the DMC phenotype resembles that of type IV 
mucopolysaccharidosis (Morquio disease), a lysosomal disorder due to either N-
acetylgalactosamine-6-sulfatase or β-galactosidase deficiency, it has also been hypothesized 
that Dymeclin has a role in intracellular digestion of proteins. However, the cellular 
phenotype of DMC rather evokes abnormal storage and/or membrane trafficking involving 
specifically the endoplasmic reticulum network. It therefore clearly differs from that of the 
Morquio disease in which ultrastructural anomalies involve lysosomes. In addition, 
biochemical analyses failed to reveal any enzymatic deficiency or accumulation of specific 
substrate in DMC cells (3).  
In order to obtain additional clues about Dymeclin function, we studied the expression pattern 
of the DYM gene in human embryonic and foetal tissues using in situ hybridization and 
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investigated the sub-cellular localization and the dynamics of the protein in living cells. We 
show that DYM transcripts are widely expressed throughout human development and that 
Dymeclin is not an integral membrane protein of the ER, but rather a peripheral membrane 
protein dynamically associated with the Golgi apparatus. Using different mutations previously 
identified in DMC and SMC patients, we show that all mutated proteins are mis-localized and 
subsequently degraded except for one particular mutation reported in SMC. 
 
 
Results 
DYM transcripts are widely expressed during human development 
Northern blot analysis of mRNA derived from human tissues previously showed that DYM 
has two transcripts (3.1 and 5.6 kb) abundantly expressed in foetal brain (2). Using two non-
overlapping riboprobes selected in either the 5’-half of DYM (probe A, 0.85 kb) or its 3’-half 
(probe B, 0.5 kb, not shown), we revealed the same two RNA species, thus confirming their 
specificity. We also show that DYM is abundantly expressed in primary chondrocytes and 
osteoblasts (Fig. 1A). Because mutations in DYM specifically affect the cognitive 
development of children and their bone growth in a progressive manner, we questioned 
whether DYM expression was specific to nervous and osseous tissues or if it was more widely 
expressed during human development. To address this question, a human multiple tissue 
expression array was probed with probe A. Consistent with a wide range of expression, DYM 
transcripts were detected in most adult tissues (Fig. 1A). Highest levels of expression were 
seen in the cerebellum, kidney, lung and stomach, but in the heart and the pancreas as well. 
However, very low or no expression was observed in the spleen, thymus, oesophagus, bladder 
and thyroid gland. DYM was also expressed in a variety of human cell types, including HeLa, 
SaOs2 and skin fibroblasts and was detected in murine ES cells (Fig. 1A).  
As to investigate the spatio-temporal expression pattern of DYM during human development, 
we performed in situ hybridization on human embryonic and foetal tissues at different 
developmental stages, Carnegie Stage 17 (CS17, 40 day embryo), Carnegie Stage 19 (CS19, 
47-48 day embryo), 17 and 22 weeks of gestation foetus. At CS17, expression of DYM was 
slightly detectable in numerous structures of the embryo, including the neural tube, the cranial 
nerve nuclei, the mandible, the stomach, and the limb bud, but no structure showed a 
particularly marked signal (data not shown). Hybridization at CS19 confirmed the widespread 
expression of DYM with a higher expression in the germinative zone of the prosencephalon, 
mesencephalon and cerebellum anlage (Fig. 1B, a,b,c) but also in mesenchymal condensations 
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of the lung and intestinal epithelia (Fig. 1B, a,d,e,f,g). Surprisingly enough, no specific signal 
could be detected in the vertebrae of the CS19 embryo. Specific expression in the cerebellum 
was confirmed at later stages. In the 17 week cerebellum, DYM was mostly expressed in the 
external granule cell layer, the germinative zone which gives rise to the internal granule 
neurons between 16 and 40 weeks (Fig. 1B, h,i,j,k). At 22 weeks of age, DYM was highly 
expressed in the external granule layer, in the Purkinje neurons and in the internal granule 
layer (Fig. 1B, p,q,r,s). At both 17 and 22 weeks, specific labelling was observed in the 
neocortical plate and corresponding ventricular zone (germinative zone) as well as in the 
hippocampus (Fig. 1B, l,m,n,o and t,u,v,w). No specific labelling was detected in areas of 
neuronal migration at any stage. 
Together, these data show that human DYM expression is not restricted to nervous and 
osseous tissues but is also expressed in most embryo-foetal and adult tissues. 
 
The DYM gene product, Dymeclin, is a Golgi-associated protein 
The coding sequence of DYM is predicted to produce a 669-aminoacid protein we have 
previously named Dymeclin (2). As to characterize Dymeclin, we generated a polyclonal 
antiserum against a 16-aminoacid peptide selected in the amino-terminal half of the protein in 
a region conserved between mouse and human. The sub-cellular localization of Dymeclin was 
assessed in HeLa cells by immunofluorescence. As shown in Figure 2A, we found 
endogenous Dymeclin in the cytosol but it was predominantly detected as a perinuclear 
pattern reminiscent of the Golgi complex. When cells were double-labelled for Dymeclin and 
GM130, a marker of the cis-Golgi, an extensive overlap was observed. Specificity of our 
antibody could be checked in immunofluorecence using a mis-localized mutant of Dymeclin 
(Fig.2A), although we did not detect a stronger Golgi labelling upon over-expression of 
exogenous Dymeclin, suggesting that Golgi localization may be saturable. We were also able 
to immunoprecipitate the recombinant protein fused to GFP at its carboxy-terminus, Dym-
GFP (~105kDa, Fig.2B). However, our antibody did not raise specific signal in western blot. 
Importantly, GFP-tagged Dymeclin was similarly found on Golgi elements. HeLa cells were 
transfected with Dym-GFP and stained for immunofluorescence using various markers of the 
cis-Golgi (GM130 and Giantin), the trans-Golgi/trans-Golgi Network (Galactosyl Transferase 
and TGN46) and of the endoplasmic reticulum (PDI, Fig. 4B). Like the endogenous protein, 
recombinant Dymeclin strongly co-localized with markers of the cis and trans-Golgi and was 
closely apposed to the TGN marker (Fig. 3A). By contrast, Dymeclin did not co-localize with 
markers of the endoplasmic reticulum (Fig. 4B). Similar results were obtained using an 
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amino-terminal GFP-tagged Dymeclin (GFP-Dym) or a myc-tagged Dymeclin (data not 
shown). Immuno-electron microscopy was used to further analyze the location of Dymeclin 
within the Golgi apparatus of HeLa cells. Immuno-gold labeling of Dym-GFP on cryosections 
confirmed the presence of Dymeclin near the membranes of the Golgi apparatus and on 
vesicular structures of transfected cells (Fig. 3B).  
No conserved domains or signal peptides could be predicted from the Dymeclin primary 
sequence, except for a putative N-terminal myristoylation site “MGSNSSR” (2). Protein N-
myristoylation corresponds to the covalent attachment of a myristate, a 14-carbon saturated 
fatty acid, to the N-terminal glycine of eukaryotic proteins and promotes, in many cases, a 
weak and reversible membrane association (8). Because the MGSNSSR site found in 
Dymeclin was N-terminal and included a glycine residue in position +2, we tested whether 
this motif could be myristoylated in vitro. Carrying out in vitro translation of wild type and a 
G2A mutant in the presence of radioactive myristate, we could show that Dymeclin can be 
myristoylated on the G at position +2 (Fig. 4A). We then asked whether myristoylation was 
essential for Dymeclin to localize to the Golgi apparatus. The mutant G2A was expressed 
fused to GFP in HeLa cells. The cells were fixed 24 hours after transfection and stained for 
immunofluorescence with the endoplasmic reticulum marker PDI. Although we observed a 
slight increase in cytosolic localization of Dym-G2A-GFP, it clearly localized on the Golgi 
apparatus (Fig. 4B). Similarly, we observed that amino-terminal tagging of Dymeclin, while it 
prevents myristoylation, does not prevent Dymeclin from binding to the Golgi apparatus (data 
not shown). Altogether, these results indicate that Dymeclin is a Golgi-associated protein and 
that myristoylation is dispensable for Dymeclin binding to the Golgi apparatus. 
 
Dymeclin is a peripheral Golgi protein 
Based of hydrophobic domain analysis, it has been proposed that Dymeclin may be a multi-
spanning transmembrane protein (7). To address this question, we used a permeabilization 
assays in living cells adapted from a protocol described by Lorenz et al. (9). HeLa cells stably 
expressing mCherry-Histone were transfected with GFP-tagged Dymeclin and observed by 
fluorescent microscopy. Cells were then treated by low concentration of digitonin to 
permeabilize the plasma membrane and observed again. While Dym-GFP was present on the 
Golgi apparatus and in the cytosol before treatment, it completely disappeared after 1 min 
upon opening of the cells (Fig. 5). We compared Dymeclin behavior to ARF1 and GRASP65 
behavior, two myristoylated proteins associated with the Golgi apparatus. Before treatment, 
Dymeclin, GRASP65 and ARF1 display very similar localization (Fig. 5 a,c,e). However, the 
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Golgi apparatus was still weakly stained by GRASP65 and ARF1 1 minute after 
permeabilization (Fig. 5 e,f) suggesting that the association of ARF1-GFP and GRASP65-
GFP with the Golgi apparatus is more stable than that of Dymeclin. Because Dymeclin was 
more rapidly released from the Golgi apparatus than two well known peripheral Golgi 
proteins that dynamically exchange with the cytosol (10 , 11), we concluded that Dymeclin is 
not a transmembrane protein but is a cytosolic protein which can be recruited to the Golgi 
apparatus. 
 
Dymeclin rapidly shuttles between the Golgi complex and the cytosol  
Because Dymeclin behaved as a peripherally associated Golgi protein and was also present in 
the cytosol, we next examined the dynamics of the protein in living cells. HeLa cells were 
transfected with GFP-tagged Dymeclin and fluorescence recovery after photobleaching 
(FRAP) experiments were performed on living HeLa cells 24 hours after transfection. GFP-
tagged ARF1 and GRASP65 were used as references for Golgi-associated myristoylated 
proteins. We measured the fraction of these proteins which is associated to the Golgi 
apparatus (Fig. 6A). As reported previously (10), we found that 16.5 ± 4% of ARF1 is Golgi-
associated. We obtained very similar values for Dymeclin (13.6 ± 3.9%) while a larger pool 
was measured for GRASP-65 (33.2 ± 10.8%). The recovery of fluorescence was quantified 
for the three proteins after correction of the photobleaching resulting from the acquisition and 
subtraction of the background. The quantifications were performed on 3D and 2D images and 
gave similar results (data not shown). We therefore decided to work with 2D images in order 
to increase the frequency of acquisition. The normalized intensity measured for 30 seconds 
after FRAP for all proteins was plotted on the same graph (Fig. 6B). When Golgi-associated 
Dym-GFP was photobleached, fluorescence recovered to the Golgi area in less than twenty 
seconds (Fig. 6D and sup. Movie 1); this recovery is faster than that of the two reference 
proteins (Fig. 6B). We calculated the mean half time of recovery and confirmed that Dym-
GFP recovers more rapidly than the two other proteins with a half time of 2.8 ± 0.9 seconds 
(Fig. 6C). Arf1-GFP, which is known to be a fast shuttling protein (10 , 11) displayed a half-
time recovery of 7.1 ± 2.6 seconds while GRASP65-GFP had a slightly slower dynamics with 
a half-time of 12.4 ± 4.5 seconds. These results demonstrate that Dymeclin is a highly mobile 
protein as the entire Golgi pool can be exchanged in less than 20 seconds. 
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Dymeclin specifically binds to a subset of the Golgi apparatus upon nocodazole 
treatment 
We have shown in the past that depolymerization of microtubules by a nocodazole treatment 
reveals the presence of two separate Golgi pools (12). Most of Golgi-associated proteins (like 
GM130 and GalT) are relocated on the newly formed mini stacks that appear after 
microtubules disassembly whereas one protein, Giantin, is found only on the old, pre-existing 
Golgi complex that keeps its juxta-nuclear localization. This may be due to the fact that 
Giantin being a very large transmembrane protein is recycling very slowly to the newly 
formed mini-stacks. In order to test whether Dymeclin recognizes a particular set of Golgi 
stacks, HeLa cells expressing Dym-GFP were left untreated or incubated for 90 minutes in the 
presence of nocodazole, before being fixed and stained for GM130 and Giantin and observed 
by immunofluorescence. The three proteins strongly co-localized in control conditions (Fig. 
7A, top line). After nocodazole treatment, and as reported before (12), GM130 was present on 
the mini stacks dispersed through the cytoplasm whereas Giantin was still located on “old” 
Golgi complexes that were present before nocodazole addition and that are still located in the 
pericentriolar region (Fig. 7A, bottom line). Surprisingly, Dym-GFP was present both as a 
soluble pool and on the “old” Golgi but not on the newly formed mini stacks. This result was 
very surprising as we have shown that Dym-GFP shuttles very rapidly between the Golgi 
apparatus and the cytosol and suggested that Dym-GFP specifically recognizes a subset of the 
Golgi apparatus. To test this hypothesis, we followed the dynamics of Dym-GFP after 
nocodazole treatment in living HeLa cells by FRAP. Cells were co-transfected with Dym-
GFP and mCherry-GM130 and treated with nocodazole 24 hours after transfection (Fig. 7B). 
As expected, GM130 was found on dispersed dots in the cytoplasm while Dymeclin was 
preferentially located in a subset of cellular structures (see the GM130-positve element 
indicated by an arrowhead in Fig. 7B). Dym-GFP was photo-bleached and its recovery 
analyzed. White arrows in Figure 7B indicate the bleached region. Dym-GFP fluorescence 
had already largely recovered after 9 seconds (top line, Dym-GFP) whereas mCherry-GM130 
did not recover during the time of acquisition (middle line, mCh-GM130). Therefore, 
Dymeclin specifically and dynamically recognizes a subset of the Golgi apparatus while it 
ignores other Golgi stacks, a behavior revealed in the absence of microtubules. 
 
 
 
Page 9 of 33 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 9 
DMC mutations but not the E87K SMC mutation result in Dymeclin mis-localization 
and subsequent protein degradation 
Most of the genetic mutations which have been identified in DMC patients are stop mutations, 
insertions and deletions causing frameshift or splice mutations that predict protein truncation 
(3). However, one missense mutation (N469Y) has been identified in some DMC patients 
while another one (E87K) has been associated with the SMC variant with no mental 
retardation (1 , 2). Since mental retardation is variable in DMC (ranging from mild to severe), 
and totally absent in SMC, we asked whether the consequence of DYM mutations on the 
protein could differ between mutations. To this end, three nonsense mutations (R204X, 
Q483X and K616X) and the two missense mutations (N469Y and E87K) were introduced 
through site-directed mutagenesis in GFP-Dym. Following over-expression of these 
constructs in HeLa cells, the localization of the five mutant proteins was analyzed and 
compared to that of wild-type GFP-Dym and GM130. Although GFP fluorescence was 
globally found very weak in cells transfected with DMC mutations, numerous small 
aggregates were observed in many cells in a pattern suggestive of protein degradation (Fig. 
8A). However cells transfected with the E87K mutation still displayed a pattern similar to that 
of the wild-type Dymeclin. Therefore, only DMC mutations resulted in a mis-localization and 
aggregation of Dymeclin. Since ubiquitin-rich cytoplasmic inclusion is linked to the 
pathogenesis of many diseases, we performed a double labelling of DMC mutants with an 
antibody raised against ubiquitin. As shown in Figure 8B, ubiquitin was found co-localized 
with mutant GFP-Dym aggregates. These results strongly suggest that DMC mutations result 
in intracellular deposition of mis-folded Dymeclin which then aggregates into ubiquitin-rich 
cytoplasmic inclusions, most likely inducing its degradation, whereas the E87K SMC 
mutation does not affect the stability and the location of the protein.  
 
 
Discussion 
Dymeclin, a new peripheral protein of the Golgi apparatus 
The gene responsible for DMC syndrome encodes a 669-aminoacid protein we have named 
Dymeclin. BLASTS, sequence motif and homology searches using multiple databases 
indicated that Dymeclin is a novel evolutionarily conserved protein with no homology or 
known conserved functional domains, except for a putative N-myristoylation site (2). Using 
electron microscopy and immunofluorescence techniques on both fixed and living cells, we 
have shown in this study that Dymeclin is a peripheral protein of the Golgi apparatus. We did 
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not observe any significant ER labeling, which is in contrast with data obtained by Osipovich 
et al (13). However, these authors used an aminoterminally tagged Dymeclin, a tagging 
position which hampers myristoylation of the protein. Despite many trials with either home-
made or commercially available antibodies (12 antibodies tested so far), specific signal for 
endogenous Dymeclin was hardly detectable in our hands by Western blot. This may be due 
to a poor ability of Dymeclin to elicit immune response or a high turn-over/instability of the 
protein in solution. However, we could detect a Golgi/cytosolic signal for many of the anti-
Dym antibodies and immunoprecipitate Dym-GFP with one of them (see Fig. 2B). Based on 
the hydrophobicity profile of the aminoacid sequence, Dymeclin was first thought to be an 
integral membrane protein with six trans-membrane segments (1). Again, owing to the very 
fast release of Dymeclin from the Golgi (Fig. 6) we could not get conclusive results from 
classical biochemical fractionation. However, using imaging experiments, we have shown that 
Dymeclin is not a stably anchored trans-membrane protein but a dynamically localized 
peripheral protein of the Golgi apparatus. Firstly, short cell permeabilization without protein 
extraction using digitonin resulted in a complete loss of both soluble and Golgi-localized 
Dymeclin. In the same condition integral membrane proteins (not shown) but also well known 
Golgi peripheral proteins like ARF1 and GRASP65 were still membrane-associated. In 
addition, FRAP experiments revealed that Dymeclin shuttles very rapidly between the cytosol 
and the Golgi apparatus. Interestingly, it is the fastest Golgi shuttling protein described so far, 
exceeding the speed observed for ARF1 and GRASP65 (our results and (14, 15)). Dymeclin is 
thus present as a cytosolic pool that can shuttle very rapidly between the cytosol and the Golgi 
apparatus, like other myristoylated proteins. However, the Golgi localization of ARF1 or 
GRASP65 depends on their myristoylation whereas Dymeclin as a second unknown 
mechanism of localization. Another striking difference which we report here is that while 
proteins like ARF1 or GRASP65 were not observed to select particular Golgi stacks, 
Dymeclin dynamically recognizes a subset of the Golgi apparatus revealed by the 
depolymerization of microtubules. The existence of two Golgi complex subsets was reported 
previously (12) but only Giantin was found to preferentially localize on the “old”, pre-
existing, Golgi apparatus. That a shuttling protein like Dymeclin can similarly recognize the 
“old” Golgi suggests that it can recognize Golgi components specifically found at the surface 
of mature Golgi apparatus and not on newly formed mini-stacks (Fig. 9 B, green) in contrast 
to other shuttling proteins like ARF1 (Fig. 9 B, red). Both to understand the role of Dymeclin 
in disease development and to characterize further Golgi complex dynamics, it will be 
important to understand how Dymeclin can recognize a subset of the Golgi apparatus and if 
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specific proteins or lipids are necessary for this localization. Because Giantin is a 
transmembrane protein of the Golgi apparatus, and is the only known marker of this mature 
Golgi compartment, it is tempting to speculate that Dymeclin is recruited on Golgi 
membranes by Giantin. Interestingly, Osipovich et al. identified Giantin as a potential 
Dymeclin partner by mass spectrophotometry analysis although this result has not be 
validated (13). 
 
DYM mutations lead to complete degradation of Dymeclin in DMC but not in SMC. 
Many mutations have been identified in DMC and SMC dysplasias which lie in various 
locations along the DYM gene (3). Although most of them predict protein truncation and a 
likely loss-of-function of Dymeclin, two different missense mutations have been associated 
specifically with DMC syndrome (N469Y, (1 , 2)) or SMC syndrome (E87K, (1 , 2)). Since 
mental retardation is constantly observed in DMC and absent in SMC, we asked whether 
these two specific amino-acid substitutions could result in different consequences on 
Dymeclin and found that the N469Y but not the E87K mutation results in mis-localization 
and subsequent protein degradation. So far, DYM mutations associated with SMC syndrome 
have been identified in only two families which share compound heterozygosity for the same 
two mutations, namely the E87K substitution (on one allele) and a splicing mutation leading 
to exon 8 skipping and a premature stop codon (on the other allele, (1 , 2)). Interestingly the 
latter mutation has been associated with DMC as well (3). Since heterozygous individuals 
who bear the exon 8 splice mutation plus one normal allele (like parents of these patients) are 
not affected, the E87K mutation appears specific to SMC phenotype. Given that this particular 
mutation neither results in Dymeclin degradation nor induces mis-localization, it is likely that 
some residual activity of Dymeclin could explain the absence of neurological phenotype in 
SMC patients. Conversely, since DMC and SMC share similar skeletal features, the E87K 
mutation likely exerts a deleterious effect in bony tissue. It will be interesting to identify the 
specific defects induced by the E87K mutation that prevent this Golgi-localized Dymeclin 
form to normally fulfill its function.  
 
What role for Dymeclin in DMC syndrome. 
Although skin anomalies are not part of the DMC phenotype, Dymeclin is present in 
fibroblasts and the ultrastructural anomalies observed in skin fibroblasts from DMC 
individuals presumably properly reflect the intracellular consequences of DYM deficiency (3). 
Indeed, electron microscopy analysis of chondrocytes from two children with Smith-McCort 
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dysplasia (SMC) also revealed a highly dilated rough endoplasmic reticulum (6). From their 
observation, the authors concluded that SMC and DMC should be rough endoplasmic 
reticulum storage disorders. However, the specific compound which would accumulate does 
not seem to be Dymeclin itself since both nonsense and missense DMC mutations result in 
degradation of the protein. Several extensive biochemical analyses, including 
incorporation/degradation assays of sulphated proteoglycans, peroxysomal and lysosomal 
contents examination, lipid, carbohydrate and protein work up and assays of mitochondrial 
respiratory chain activities were performed by our group and others. However, no enzymatic 
deficiency or specific accumulated compound in DMC cells which would have been 
consistent with a specific storage of a putative mis-degraded metabolite could be found (3 , 16 
, 17 , 18 , 19). Although we can not rule out the possibility that DMC and SMC would be the 
consequence of a metabolic perturbation which we were unable to characterize yet, our data 
provide a body of arguments in favor of an ER-Golgi membrane trafficking disorder. 
However, experiments we carried out on DMC fibroblasts failed to reveal a reproducible 
defect in anterograde and retrograde membrane trafficking (data not shown). This may not be 
surprising because fibroblast cells are to affected in DMC patients. This is nevertheless in 
marked contrast with results reported by Osipovich et al., although the effects were not 
quantified by the authors (13). Dymeclin has common features with other Golgi proteins such 
as GRASP65 or ARF1. These three proteins are localized to the Golgi apparatus, they are 
myristoylated and they shuttle rapidly between a cytosolic pool and a Golgi pool. Dymeclin 
could therefore be involved in a GRASP like function and have a role in the structure and/or 
the function of the Golgi apparatus. GRASP65 has been involved in the formation of the 
mitotic spindle (20) but also in the fusion of the Golgi ribbons (21). In drosophila, the 
GRASP65 homologue is involved in non-conventional secretion (22) A related protein, 
GRASP55 was recently shown to be similarly involved in Golgi unlinking (23). Interestingly, 
unlinked Golgi cisternae are reminiscent of nocodazole-generated mini-stacks that cannot be 
recognized by Dymeclin. Structural defects were actually observed in patient cells which 
further argue for a role of Dymeclin in the regulation of Golgi apparatus organization.  
Dymeclin could also have a role similar to the role played by ARF1 or Sar1 and be important 
for the formation of a complex of proteins (like COPI or COPII respectively) involved in a 
step of the intracellular transport (24 , 25). This hypothesis could also explain the defects 
observed by electron microscopy in patient fibroblasts. In this context, it is interesting to note 
that a mutation in a component of the COPII coat component Sec23A leads to cranio-
lenticulo-sutural dysplasia (26). In fibroblasts from these patients, the ER appears swollen and 
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many tubular protrusions were observed (27). Sec23A is an ubiquitous protein, like Dymeclin, 
which is essential for intracellular transport but only affects some cell types. 
Most of inherited diseases known to be associated with ER-Golgi anomalies involve cargo 
molecules that become unable to couple to the export machinery and then either undergo 
degradation or accumulate in the cell (28 , 29 , 30). So far, few genetic disorders have been 
reported to involve central constituents of the ER-Golgi budding, presumably because their 
disruption is lethal. One of them, however, the X-linked skeletal disorder Spondyloepiphyseal 
dysplasia tarda (SEDT, MIM #313400), is viable and associated with a loss-of-function of 
Sedlin, the functional counterpart of the yeast transport protein particle (TRAPP) Trs20p (31 , 
32). Interestingly, TRAPP is a large cytosolic protein complex (~ 1,000 kDa) required for 
tethering ER-derived vesicles to Golgi membranes and for intra-Golgi traffic. In addition, 
SEDT is characterized by several features strikingly reminiscent of DMC (3 , 33): i) both 
diseases are chondrodysplasias with short-trunk dwarfism, ii) in both cases, the phenotype is 
not obvious at birth and appears progressively in childhood and iii) in both diseases, clinical 
features specifically include a broad chest with sternal protrusion and a flattened and humped 
appearance of the vertebral bodies. Although Dymeclin does not share any sequence 
homology with Sedlin, it is tempting to speculate that the two proteins may have a functional 
relationship in cartilage differentiation.  
It will now be important to unravel Dymeclin's connection to other regulators of ER/Golgi 
dynamics and function to understand better the role that this protein plays in the development 
of the DMC/SMCdysplasias. 
 
 
Materials and Methods 
Multiple-tissue expression array and Northern blot 
Pre-made human multiple-tissue expression array (MTE; ref 7776-1 Clontech Laboratories) 
and Northern blot containing 20 µg of total RNA extracted from human primary 
chondrocytes, calvarial osteoblasts, immortalized chondrocytes, SaOs2, HeLa and murine ES 
cells were hybridized overnight at 42°C with either a 0.85 kb cDNA fragment corresponding 
to the 5’-end of DYM (probe A) or a 0.5 kb cDNA fragment selected in the 3’-end of Dym 
(probe B), labelled and purified as previously described (2). Primers used to generate probe A 
were selected in exons 2 and 9 (2). Primers used to generate probe B were selected in exon 10 
(10Sintra: 5’-CTCCTCTTGTATACCTTGCT-3’) and exon 14 (8ASintra: 5’-
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AGGAACATCATTAGAACTCAG-3’). Blots were washed three times at 42 °C with 
2×SSC : 0.1% SDS for 15 minutes and once under more stringent conditions, at 65 °C with 
0.1×SSC : 0.1% SDS for 10 minutes and further exposed overnight to Kodak X-Omat films 
with an intensifying screen at -80 °C. 
 
In situ hybridization 
Human embryos and foetal tissues were collected from legally terminated pregnancies in 
agreement with the French law and Ethics Committee recommendations. Tissues were fixed 
in 4% paraformaldehyde, embedded in paraffin blocks and sectioned (5 µm). Primers located 
in exon 7 (7F: 5’-AAGAAGTTTTGCGACAGAGC-3’) and exon 9 (9R:5’-
GGCCAGAGGGGAAGAAAG-3’) of DYM cDNA were selected for PCR amplification of a 
315 bp product. A T7 promoter sequence extension (5’-
TAATACGACTCACTATAGGGAGA-3’) was added at the 5’ end of each primer. T7-7F/9R 
and 7F/T7-9R sets allowed amplification of sense and antisense templates. Ribobropes were 
labelled using T7 polymerase in the presence of α[35S]UTP (1200 Ci/mmol; NEN) and 
purified on Sephadex G50 columns. Hybridization and post-hybridization washes were 
carried out according to standard protocols (34). Slides were dehydrated, exposed to 
BIOMAX MR X-ray films (Amersham) for 3 days, dipped in Kodak NTB2 emulsion for 3 
weeks at +4 °C, then developed and counterstained in toluidine blue, coverslipped with 
Eukitt, and analysed under dark and bright field illumination. No hybridization signal was 
detected with the α[35S]-labelled sense probe. 
 
Plasmids and site-directed mutagenesis 
The coding region of human DYM cDNA (FLJ90130, DDBJ/EMBL/Genbank accession 
number AK074611) was purchased from the Biological Resource Center, Japan (NBRC) as 
an insert cloned into the pME18SFL3 plasmid. However, the clone differed by two 
nucleotides from the human sequence we previously identified (2) changing a glutamate into a 
lysine at codon 66 and a leucine into a proline at codon 249. These two mismatches were 
corrected using the QuickChange XL site directed in vitro mutagenesis kit, following the 
manufacturer’s instructions (Stratagene). The cDNA of DYM was amplified by PCR and 
subcloned in the pEGFP-N2 vector (Clontech) between XhoI and BamHI. The QuickChange 
XL site directed in vitro mutagenesis kit was used to generate the R204X, Q483X, K616X, 
E87K and N469Y mutations. Primers designed to mutate the myristoylation site of Dymeclin 
were as follow: G2Afor, 5’-AGCTTGAAGATGGCATCGAATAGCAGC-3’, G2Arev, 5’-
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GCTGCTATTCGATGCCATCTTCAAGCT-3’. In FRAP analyses, we used pEGFP ARF1 
and pEGFP GRASP65 (kindly provided by F. Barr). All constructs were verified by direct 
sequencing using the ABI PRISM BigDye Terminator Cycle Sequencing Reaction Kit on an 
automatic ABI3100 capillary sequencer (Applied Biosystems). 
 
Cell culture and transfection 
HeLa cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) containing 
4.5 g/l glucose supplemented with 10% fetal calf serum, 5 mM glutamine, 5 mM sodium 
pyruvate at 37 °C in a 5% CO2 humidified incubator. For transfections, cells were plated on 
coverslips the day before transfection, and were transfected using lipofectamin 2000 
(Invitrogen). The cells were fixed with either 100% methanol at -20°C for 5 minutes or 3% 
PFA at room temperature for 15 minutes, washed with PBS, incubated with PBS-0,1M 
NH4Cl for 5 minutes, washed again with PBS and permeabilized with 0,1% Triton X100 for 5 
minutes. 
 
Immunoprecipitation 
Immunoprecipitations were carried out by using extracts prepared from HeLa cells over-
expressing Dym-GFP with the Protein G-agarose Immunoprecipitation kit from Roche. 
Briefly, cell lysates were first incubated on a rocking platform 5 hours at 4 °C with 50 µl of 
the homogeneous G-suspension and centrifuged 20 seconds at 12000 g. The supernatant was 
then incubated with 2-4 µg of mouse monoclonal anti-GFP antibody (Roche) overnight at 4 
°C and another 50 µl of the homogeneous G-suspension was added for 5 hours. After several 
washes of the complexes, the immunoprecipitated proteins were separated by SDS-PAGE and 
electroblotted on PVDF membranes (Immobilon, Millipore). The membranes were pre-
incubated for 1 hour at 4 °C in TBS (20 mM Tris-HCl ph7.4, 150 mM NaCl) containing 5% 
skim milk. The blots were then incubated overnight at 4 °C with either anti-GFP (control) or 
anti-Dym antibodies both at dilutions of 1/1000. After membrane washing, a second antibody 
coupled to peroxidase was added. Proteins were visualized with the ECL detection kit 
(Amersham). 
 
Permeabilization assays and drugs 
For permeabilization assays, cells grown on a glass bottom chamber (Iwaki) were treated 
directly during imaging with 60 µM digitonin for 1 minute. For Nocodazole treatment, cells 
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were first incubated at 4 °C for 1h30, then at 37 °C for 1h30 in the presence of 10 µM 
Nocodazole (Sigma) before being directly fixed or used for imaging. 
 
Immunofluorescence 
Primary antibodies: anti-giantin hFc TA10 1/50, polyclonal anti-GalT 1/1000, sheep TGN46 
1/1000, anti-GM130 (Transduction Laboratories, 1/200), anti-transferin receptor OKT9 1/500, 
DAPI 1/1000. Secondary antibodies: anti-human Cy3 (Jackson, 1/500), anti-rabbit Cy5 1/500, 
anti-mouse Cy3 1/500, anti-sheep Cy3 1/500, anti-mouse Cy5 1/500, anti-human Cy5 1/500. 
Fixed cells were visualized using a Leica DM6000B microscope with a CoolSnapHQ camera 
(obj 100x NA 1.4 oil CS (HCX PL APO), or with a Leica DMRA and a Micromax 5 Mhz, 
40x objective NA 1.25 oil ph3 CS (HCX PL APO), and Metamorph. 3D stacks were acquired 
and deconvolved to build a projection on one plane on Metamorph. 
 
Live imaging 
For FRAP analyses with Dym-GFP, ARF1-GFP and GRASP65-GFP. HeLa cells were 
maintained in culture medium in glass bottom chambers (Iwaki) and imaged on a Leica 
DMIRE2 with a Roper Cascade II Camera, Polychrome V and a 100x NA 1.35 oil oblective, 
twenty-four hours after transfection. Images were collected before bleaching of the Golgi and 
every 50 milliseconds after photobleaching. Images were processed using Metamorph 
software. After correction of the photobleaching due to acquisition, the background was 
subtracted. The intensity of fluorescence was then normalized and the half recovery was 
quantified. For nocodazole treated cells the images were acquired on a spinning disk 
microscope. The Spinning disk microscope is based on a CSU-22 Yokogawa head mounted 
on an inverted TE-2000E Nikon microscope equipped with a motorized Märzhäuser XY 
Stage. Images are acquired through a 60x 1.4NA Plan-Apo objective with a Photometrics 
Coolsnap HQ2 CCD camera. Optical sectioning is achieved using a PI Pifoc piezo z-drive 
mounted between the microscope turret and the objective. A Roper/Errol laser lounge is 
equipped with 488 nm and 514 nm laser diodes, delivering 50 mW each, coupled to the 
spinning disk head through a single fiber. Multi-dimensional acquisitions are performed in 
streaming mode using Metamorph 7.1.7 software. Images were collected before bleaching of 
the Golgi and every 400 milliseconds after photobleaching for Dym-GFP and mCherry-
GM130. The data shown in the movies where obtained using ND-SAFIR (N-Dimensional – 
Structure Adaptive Filtering for Image Restoration) © INRIA/INRA 2007 as previously 
described (35 , 36). 
Page 17 of 33 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 17 
 
Immunoelectron microscopy  
Briefly, cells were fixed with 2% paraformaldehyde, 0.125% glutaraldehyde in culture 
medium for 30 minutes at 37 °C. This medium was removed and replaced by PFA 2% + 
0,125% glutaraldehyde in phosphate buffer pH 7,4 for 2 hours at 37 °C. This fixative was 
replaced by PFA 2% in phosphate buffer pH 7,4. Cells were then processed for 
ultracryomicrotomy as previously described (37). Ultrathin cryosections were prepared with 
an ultracryomicrotome Ultracut FCS (Leica, Vienna, Austria) and immunogold labeled with 
the indicated primary antibodies and using protein A conjugated to 10 nm gold (Cell 
Microscopy Center, AZU, Utrecht, The Netherlands). Sections were analyzed under a Philips 
CM120 electron microscope, and digital acquisitions were made with a numeric camera Keen 
View (Soft Imaging Systems, Münster, Germany). 
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Legends to figures 
 
Figure 1: Expression of Dym throughout human development  
A: Tissue distribution of human Dym transcripts. MTE array was probed with an 850 bp 
human Dym radiolabeled probe (probe A) as described in experimental procedures and spots 
corresponding to the most intense expressions (up to 100 arbitrary units) were quantified 
using Sigmagel (Jandel Scientific, v1.0). The identity of each cDNA dot is as follows: A1, 
whole brain, A2, cerebellum left, A3, substantia nigra, A4, heart, A5, esophagus, A6, colon 
transverse, A7, kidney, A8, lung, A9, liver, A10, leukaemia HL-60, A11, fetal brain, A12, 
yeast total RNA, B1, cerebral cortex, B2, cerebellum right, B3, nucleus accumbens, B4, aorta, 
B5, stomach, B6, colon desending, B7, skeletal muscle, B8, placenta, B9, pancreas, B10, 
HeLa S3, B11, fetal heart,  B12, yeast tRNA, C1 frontal lobe, C2, corpus callosum, C3, 
thalamus, C4, atrium left, C5, duodenum, C6, rectum, C7, spleen, C8, bladder, C9, adrenal 
gland, C10, leukaemia K-562, C11, fetal kidney, C12, E.coli rRNA, D1, parietal lobe, D2, 
amygdala, D3, pituary gland, D4, atrium right, D5, jejunum, D7, thymus, D8, uterus, D9, 
thyroid gland, D10, leukaemia MOLT-4, D11, fetal liver, D12, E.coli DNA, E1, occipital 
lobe, E2, caudate nucleus, E3, spinal cord, E4, ventricle left, E5, ileum, E7, peripheral blood 
leukocytes, E8, prostate, E9, salivary gland, E10, Burkitt’s lymphoma, Raji, E11, fetal spleen, 
E12, poly r(A), F1, temporal lobe, F2, hippocampus, F4, ventricle right, F5, ileocecum, F7, 
lymph node, F8, testis, F9,mammary gland,  F10, Burkitt’s lymphoma, Daudi,  F11, fetal 
thymus, F12, human Cot-1 DNA, G1, paracentral gyrus of cerebral cortex, G2, medulla 
oblongata, G4, interventricular septum, G5, appendix,  G7, bone marrow, G8, ovary, G10, 
colorectal adenocarcinoma SW480, G11, fetal lung, G12, human DNA 100ng, H1, pons, H2, 
putamen, H4, apex of the heart, H5, colon ascending, H7, trachea, H10, lung carcinoma, 
A549, H12, human DNA 500ng. No sample was spotted in F3-H3, D6-H6, H8, H9, H11 and 
G9. C, Northern blot analysis was performed using probe A, which recognizes two Dym 
variants (3.1 kb and 5.6 kb). The amount in each lane is normalized with RNA 18s. 
 
B: In situ hybridization analysis of Dym transcripts during human embryo-foetal 
development. Hematoxylin/eosin stained sections under bright field illumination (A, D, F, H, 
J, L, N, P, R, T, V) and adjacent Dym-hybridized sections under dark field illumination (B, C, 
E, G, I, K, M, O, Q, S, U, W). A-C, Sagittal sections of a CS19 embryo (x10); as a negative 
control of hybridization, the sense Dym probe was used (C). D-E, Magnification of the lung 
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(Lu, x25, D) and the intestinal epithelium (x32, F, G) corresponding to the black squares in A; 
White arrows point to elective signal seen in mesenchymal condensations (E). H-K, 
Transversal sections of the cerebellum from a 17-week foetus (x10, H, I) and x32 
magnification showing Dym expression in the external granule layer (J, K). L-M, Dym 
expression in the hippocampus from a 17-week foetus (x8). N-O, Dym expression in the 
neocortical plate and in the corresponding germinative zone from a 17-week foetus (x12). P-
S, Dym expression in the cerebellum from a 22-week foetus (x8) and higher magnification 
showing Dym expression in the external granule layer, the Purkinje neurons and the internal 
granule layer (x40, R and S). T-U, Dym expression in the hippocampus from a 22-week 
foetus (x40). V-W, Dym expression in the neocortical plate and in the corresponding 
germinative zone from a 22-week foetus (x12). 
  
Figure 2: Immuno-detection of endogeneous Dymeclin in HeLa cells. A: Intracellular 
localization of endogeneous Dymeclin in HeLa cells. HeLa cells (Top panel) were fixed and 
stained with the anti-Dym antibody at dilution 1/400. The Golgi was labeled with GM130 
(red). Hela cells transfected with Dym(N469Y)-GFP (Bottom panel) were fixed and stained 
for Dymeclin (red) and GM130 (pink). B: Immunoprecipitation of Dym-GFP. Lysates from 
HeLa cells over-expression Dym-GFP (lane 1) were immunoprecipitated with either the anti-
GFP antibody (lane 2) or the anti-Dym antibody (lane 3).  
 
Figure 3: Intracellular localization of Dym-GFP in HeLa cells. A: Reconstruction from 3D 
images of HeLa cells transfected with Dym-GFP and stained with antibodies against Giantin 
(in red, top line) and GalT (in blue, top line) or TGN46 (in red, bottom line) and GM130 (in 
blue, bottom line). Dym-GFP partially co-localized with the different Golgi markers and was 
also found as a soluble pool. B: Immunogold labeling on cryosections of Dym-GFP 
transfected HeLa cells visualized by electron microscopy confirmed that the protein is 
localized on the Golgi apparatus and in the cytosol. 
 
Figure 4: Myristoylation of Dymeclin in vitro and intracellular localization of the G2A 
mutant in HeLa cells. A: Dymeclin was produced in vitro in the presence of either 35S-
methionine (left panel) or 3H-myristate (right panel). Wild-type Dymeclin (Dym WT) can be 
myristoylated in vitro and the mutation of the second Glycine into an Alanine (Dym G2A) 
prevents the myristoylation. B: Hela cells were transfected with Dym-GFP or Dym-G2A-GFP 
(green) and stained for GM130 (red). 
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Figure 5: In vivo permeabilization with Digitonin. Hela cells stably expressing mCherry-
Histone were transfected with either Dym-GFP, ARF1-GFP or GRASP65-GFP. 3D images 
were acquired on a spinning disk microscope before treatment and one minute after treatment 
with 60µM Digitonin. In permeabilized cells Dym-GFP has completely disappeared from the 
Golgi and the cytosol whereas ARF1-GFP is dimly visible on the Golgi apparatus and 
GRASP65-GFP is still present. 
 
Figure 6: Quantification of Dym-GFP dynamics. Hela cells were transfected with either 
Dym-GFP, Arf1-GFP or GRASP65-GFP and photobleaching experiments were performed 24 
hours after. A. The Golgi apparatus of one cell (outlined in white in the movie) was bleached 
after 10 seconds and images were then acquired every 100 mseconds for 1 minute (see mov. 
1). After 13,5 seconds the fluorescence of Dym-GFP has totally recovered. From these 
experiments we could quantify the Golgi fraction of the three proteins. The percentage of 
protein on the Golgi is represented in B. 16,5 ±4% of Arf1-GFP, 13,6 ± 3,9% of Dymeclin 
and 33,2 ± 10,8% of GRASP65-GFP are on the Golgi. The normalized intensity of 
fluorescence for the three proteins was plotted on the same graph. The mean value is indicated 
in black and the SD is indicated in grey. The half time of recovery was calculated from these 
data as shown in C. GRASP65-GFP recovered more slowly with a half time of 12,4 ± 4,5 
seconds, the recovery of Arf1-GFP was faster with a  half time of 7,1 ± 2,6 seconds and Dym-
GFP was even faster with a half time of recovery of 2,8 ± 0,9 seconds.   
 
Figure 7: Intracellular localization and dynamics of Dym-GFP upon nocodazole 
treatment. A: HeLa cells transfected with Dym-GFP were fixed 24 hours after transfection 
and the Golgi was labeled with GM130 (red) and Giantin (blue). In non treated cells (top line) 
the three markers co-localized whereas after 1h30 at 4°C and 1h30 at 37°C with 10µM 
nocodazole (bottom line) GM130 was present on the mini stacks dispersed in the cell and 
Giantin and Dym-GFP were co-localized on the “Old Golgi” in the center of the cell. B: 
FRAP experiments were performed on cells co-transfected with mCherry-GM130 and Dym-
GFP (see sup. Movie 2). The first line shows the Dym-GFP before (-1”), immediately after 
(0”) or 9 seconds after (9”) the photobleaching (indicated by the white arrows). The second 
line shows the mCherry-GM130 and the last line corresponds to the overlay of Dym-GFP in 
green and mCherry-GM130 in red. The insert shows the upper bleach region with a three 
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times magnification. Dym-GFP is present on the “Old Golgi” but not on the mini stacks that 
are only positive for GM130. After photobleaching of the “Old Golgi” both Dym-GFP 
fluorescence and mCherry-GM130 fluorescence are decreased. The recovery of Dym-GFP is 
complete within 9 seconds whereas mCherry-GM130 has not recovered. 
 
Figure 8: Mis-localization and degradation of Dymeclin bearing DMC mutations. A: 
HeLa cells transfected with wild-type (WT) or mutant GFP-Dym (K616X, Q483X, R204X, 
N469Y, E87K) were fixed 24 hours after transfection and the Golgi was labeled with GM130 
(red). B: HeLa cells transfected with GFP-Dym(R204X) or GFP-Dym(N469Y) were fixed 24 
hours after transfection and labeled with an anti-ubiquitin antibody (red). Ubiquitin was found 
co-localized with mutant GFP-Dym aggregates. 
 
Figure 9: Schematic representation of Dymeclin dynamic localization. A: This model 
proposes that, in the non treated cells, Dymeclin (in green) and Arf1 (in red) are present as a 
soluble pool and a Golgi pool and shuttle rapidly between the two (green and red arrows). B: 
In nocodazole treated cells Arf1 is localized on the “Old Golgi” and on the newly formed 
mini stacks whereas Dymeclin is present only on the “Old Golgi” and not on the mini stacks. 
Both proteins exchange rapidly. 
 
 
Movies captions (Quick Time format) 
Movie 1: DymFRAP.mov 
FRAP analysis of Dym-GFP in live transfected HeLa cells showing the rapid replenishment 
of Dym-GFP fluorescence in the Golgi apparatus after photobleaching. For details, see 
Dimitrov et al, Figure 6. 
  
 
Movie 2: Dym-GM130_Nz-FRAP.mov 
FRAP analysis of Dym-GFP and mCherry-GM130 in live transfected HeLa cells, incubated at 
4°C for 1h30 and treated with 10µM nocodazole at 37°C, showing no replenishment of 
mCherry-GM130 and rapid replenishment of Dym-GFP fluorescence in the “Old Golgi” after 
photobleaching. For details, see Dimitrov et al, Figure 7. 
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